Case report: The first case of concurrent breast myeloid sarcoma and borderline phyllodes tumor with malignant features
Frontiers in Oncology · 19.01.2024 · 13
DOI: 10.3389/fonc.2023.1268617 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 19.01.2024. Verfasst von Li Chun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Oncology (Rehabilitation Technology), Sichuan Nursing Vocational College, Chengdu, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myeloid sarcoma (MS) is a rare hematological malignancy characterized by the formation of a solid mass of myeloblasts outside the bone marrow, such as in the lymph nodes, skin, or bone. MS may arise de novo or concurrently with acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), or myelodysplastic syndrome (MDS). MS accounts for less than 1% of extramedullary acute myeloid leukemia cases. Phyllodes tumors (PTs) are a rare fibroepithelial breast tumor that can be benign, malignant, or borderline, and account for less than 1% of all breast cancers. Case presentation We present a unique case of a 50-year-old woman with both breast MS and borderline PT with malignant features, which presented a diagnostic challenge. The patient initially presented with a mass in her right breast, and the initial fine-needle biopsy revealed the presence of immature myeloperoxidase (MPO) + myeloid cells consistent with MS. Subsequent pathological analysis of tumor tissues after neoadjuvant radiotherapy and chemotherapy showed a borderline PT with malignant features. Following excision of the tumor, the patient experienced a local recurrence, which was also surgically removed. At 8 months post-surgery, the patient remains free of recurrence under close follow-up.
Conclusion
This case highlights the importance of considering the possibility of concurrent malignancies in the differential diagnosis of complex breast masses and underscores the challenges involved in diagnosing and managing such cases. Additionally, we also emphasize the value of neoadjuvant radiotherapy and chemotherapy in MS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Integrative Oncology (Rehabilitation Technology), Sichuan Nursing Vocational College, Chengdu, China.
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States.
- Department of Breast Surgery, Chengdu Seventh People's Hospital, Chengdu, China.
Zitieren
APA
Chun, L., Zeng, Z., Guo, Q., & He, Y. (2024). Case report: The first case of concurrent breast myeloid sarcoma and borderline phyllodes tumor with malignant features. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1268617
Vancouver
Chun L, Zeng Z, Guo Q, He Y. Case report: The first case of concurrent breast myeloid sarcoma and borderline phyllodes tumor with malignant features. Frontiers in Oncology. 2024;13. doi:10.3389/fonc.2023.1268617
BibTeX
@article{Chun2024,
author = {Chun, Li and Zeng, Zhen and Guo, Qianyu and He, Yangjun},
title = {Case report: The first case of concurrent breast myeloid sarcoma and borderline phyllodes tumor with malignant features},
journal = {Frontiers in Oncology},
year = {2024},
volume = {13},
doi = {10.3389/fonc.2023.1268617}
}
EUVIMED